Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
This section of the website contains promotional information intended for UK Healthcare Professionals only. If you are not a UK healthcare professional, please click here. GB‑NON‑07725 | Date of Preparation: August 2023
For information regarding KEYTRUDA® (pembrolizumab), please click on the relevant button below for information tailored to your needs.
Reporting side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.
Great Britain:
Summary of Product Characteristics | Patient Information Leaflet
Northern Ireland:
Summary of Product Characteristics | Patient Information Leaflet
To contact us please telephone 0208 154 8000 or email medicalinformationuk@msd.com
GB-PDO-02344 | Date of Preparation: August 2022
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000)
